Cicaderma
Radiation Toxicity
Centre Leon BerardPhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Radiation Toxicity cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM IRCCS San Raffaele | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Sun Yat-sen University | Phase 3 | BB |
ETOPOSIDE Sun Yat-sen University | Phase 3 | BB |
Amifostine Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Carboplatin Sun Yat-sen University | Phase 3 | BB |
View all 37 →
Same molecule, other indications
Cicaderma is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →